Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer

Published:2020-07 Issue: Volume:134 Page:29-40
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Zhou Tie,Xu Weidong,Zhang Wei,Sun Ye,Yan Honghua,Gao Xu,Wang Fubo,Zhou Qianxiang,Hou Jianguo,Ren Shancheng,Yang Qing,Yang Bo,Xu Chuanliang,Zhou Qingqing,Wang Meiyu,Chen Chunyun,Sun Yinghao

Funder

Suzhou Kintor Pharmaceuticals

Shanghai Changhai GCP Platform

National Major Scientific and Technological Special Project

Shanghai Sailing Program

Second Military Medical University Youth Program

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference22 articles.

1. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

2. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study;Berthold;J Clin Oncol,2008

3. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor;Mizokami;Cancer Res,2004

4. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis;Scher;J Clin Oncol,2005

5. Long-term stability of international reference preparations for thromboplastins;van den Besselaar;Br J Haematol,1988

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiandrogens as Therapies for COVID-19: A Systematic Review;Cancers;2024-01-10

2. Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response;Proceedings of the National Academy of Sciences;2023-07-17

3. Consensus on safety management of novel hormonal therapy for advanced prostate cancer;UroPrecision;2023-06

4. Proxalutamide in metastatic castration‐resistant prostate cancer: Primary analysis of a multicenter, randomized, open‐label, phase 2 trial;International Journal of Cancer;2023-04-10

5. A partially open conformation of an androgen receptor ligand-binding domain with drug-resistance mutations;Acta Crystallographica Section F Structural Biology Communications;2023-03-30